SEARCH

SEARCH BY CITATION

References

  • 1
    von Willebrand EA. Hereditar pseudohemofili. Finska Lakaresallskapets Handlingar 1926; LXVII: 87112.
  • 2
    Nilsson IM, Blomback M, Jorpes E, Blomback B, Johansson SA. von Willebrand's disease and its correction with human plasma fraction 1–0. Acta Medica Scandinavica 1957; 159: 17988.
  • 3
    Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against anti. J Clin Invest 1971; 50: 24454.
  • 4
    Zimmerman TS, Hoyer LW, Dickson L, Edgington TS. Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med 1975; 86: 1529.
  • 5
    Peake IR, Bloom AL, Giddings JC. Inherited variants of factor-VIII-related protein in von Willebrand's disease. N Engl J Med 1974; 291: 11317.
  • 6
    Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease. Blood 1987; 70: 895904.
  • 7
    Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985; 82: 63948.
  • 8
    Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, Orkin SH. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 14016.
  • 9
    Lynch DC, Zimmerman TS, Collins CJ, Brown M, Morin MJ, Ling EH, Livingston DM. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985; 41: 4956.
  • 10
    Verweij CL, De Vries CJ, Distel B, Van Zonneveld AJ, van Kessel AG, van Mourik JA, Pannekoek H. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res 1985; 13: 4699717.
  • 11
    Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 1951427.
  • 12
    Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 25369.
  • 13
    Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 317184.
  • 14
    Montgomery RR, Zimmerman TS. von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest 1978; 61: 1498507.
  • 15
    Ruggeri ZM. von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 133542.
  • 16
    Koppelman SJ, van Hoeij M, Vink T, Lankhof H, Schiphorst ME, Damas C, Vlot AJ, Wise R, Bouma BN, Sixma JJ. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87: 2292300.
  • 17
    Zhou Y-F, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. Blood 2012; 120: 44958.
  • 18
    Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: identification of a large precursor polypeptide chain. J Biol Chem 1983; 258: 20657.
  • 19
    Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76: 11026.
  • 20
    Zanardelli S, Crawley JT, Chion CK, Lam JK, Preston RJ, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006; 281: 155563.
  • 21
    Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009; 324: 13304.
  • 22
    Byams VR, Kouides PA, Kulkarni R, Baker JR, Brown DL, Gill JC, Grant AM, James AH, Konkle BA, Maahs J, Dumas MM, McAlister S, Nance D, Nugent D, Philipp CS, Soucie JM, Stang E. Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia 2011; 17(Suppl. 1): 613.
  • 23
    Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004; 111: 73440.
  • 24
    Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus “variants”. Blood 1980; 56: 71216.
  • 25
    Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 210314.
  • 26
    Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Perez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6: 76271.
  • 27
    Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001; 14: 36579.
  • 28
    Trasi S, Mohanty D, Shetty S, Ghosh K. Prenatal diagnosis of von Willebrand disease in a family. Natl Med J India 2008; 18: 1878.
  • 29
    Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia 2008; 14: 1099111.
  • 30
    Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 145965.
  • 31
    Ngo KY, Glotz VT, Koziol JA, Lynch DC, Gitschier J, Ranieri P, Ciavarella N, Ruggeri ZM, Zimmerman TS. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 27537.
  • 32
    James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand Disease. Blood 2013. Epub ahead of print.
  • 33
    Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 26470.
  • 34
    Baronciani L, Federici AB, Cozzi G, La Marca S, Punzo M, Rubini V, Canciani MT, Mannucci PM. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease. Haemophilia 2008; 14: 54955.
  • 35
    Sutherland MS, Keeney S, Bolton-Maggs PHB, Hay CRM, Will A, Cumming AM. The mutation spectrum associated with type 3 von Willebrand disease in a cohort of patients from the north west of England. Haemophilia 2009; 15: 104857.
  • 36
    Bowman M, Tuttle A, Notley C, Brown C, Tinlin S, Deforest M, Leggo J, Blanchette VS, Lillicrap D, James P. The genetics of Canadian Type 3 von Willebrand disease (VWD): further evidence for co-dominant inheritance of mutant alleles. J Thromb Haemost 2013; 11: 51220.
  • 37
    Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 48591.
  • 38
    Chandler WL, Peerschke EIB, Castellone DD, Meijer P. von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135: 8629.
  • 39
    Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171232.
  • 40
    James P, Lillicrap D. Genetic testing for von Willebrand disease: the Canadian experience. Semin Thromb Hemost 2006; 32: 54652.
  • 41
    Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 442430.
  • 42
    Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood 2012; 119: 454353.
  • 43
    Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Semin Thromb Hemost 2007; 33: 7806.
  • 44
    Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2008; 113: 52634.
  • 45
    James PD, Notley C, Hegadorn C, Poon MC, Walker I, Rapson D, Lillicrap D. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. J Thromb Haemost 2007; 5: 191422.
  • 46
    Romijn RA, Bouma B, Wuyster W, Gros P, Kroon J, Sixma JJ, Huizinga EG. Identification of the collagen-binding site of the von Willebrand factor A3-domain. J Biol Chem 2001; 276: 998591.
  • 47
    Denis C, Baruch D, Kielty CM, Ajzenberg N, Christophe O, Meyer D. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Art Thromb Vasc Biol 1993; 13: 398406.
  • 48
    Flood VH, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Lentz SR, Montgomery RR. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost 2012; 10: 141724.
  • 49
    Ribba AS, Loisel I, Lavergne JM, Juhan-Vague I, Obert B, Cherel G, Meyer D, Girma JP. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001; 86: 84854.
  • 50
    Riddell A, Gomez K, Millar C, Mellars G, Brown S, Gill S, Laffan M, McKinnon TAJ. Characterisation of W1745C and S1783A, two novel collagen binding defects in the A3 domain of von Willebrand factor. Blood 2009; 114: 348996.
  • 51
    Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, Montgomery RR. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010; 8: 14313.
  • 52
    Flood VH, Gill JC, Christopherson PA, Wren JS, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost 2012; 10: 142532.
  • 53
    Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33: 72744.
  • 54
    Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009; 35: 6075.
  • 55
    Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992; 67: 3916.
  • 56
    Mazurier C, Hilbert L. Type 2N von Willebrand disease. Curr Hematol Rep 2005; 4: 3508.
  • 57
    Mohlke KL, Ginsburg D. von Willebrand disease and quantitative variation in von Willebrand factor. J Lab Clin Med 1997; 130: 25261.
  • 58
    Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi SM, Baronciani L, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 11221.
  • 59
    James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 14554.
  • 60
    Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 63041.
  • 61
    Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood 2012; 119: 213540.
  • 62
    Wang QY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL. Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost 2012; 11: 2619.
  • 63
    Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2010; 8: 612.
  • 64
    Peake IR, Goodeve AC. Genetic testing for von Willebrand disease: the case for. J Thromb Haemost 2010; 8: 1316.
  • 65
    Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 334451.
  • 66
    Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FGH, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111: 497985.
  • 67
    Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111: 35319.
  • 68
    Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med 2001; 344: 17739.
  • 69
    Pierce GF, Lillicrap D, Pipe SW, VandenDriessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 2007; 5: 9016.
  • 70
    Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 20328.
  • 71
    Kingman CEC, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111: 14258.
  • 72
    Turecek PL, Schrenk G, Rottensteiner H, Varadi K, Bevers E, Lenting P, Ilk N, Sleytr UB, Ehrlich HJ, Schwarz HP. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost 2010; 36: 51021.
  • 73
    Suiter T, Laffan MA, Mannucci PM, Kempton CL, Romond EH, Shapiro AD, Birschmann I, Cox GJ, Ragni MV, Turecek PL, Ewenstein BM. Recombinant human von Willebrand factor (rhVWF): first in-human study evaluating pharmacokinetics, demonstrating safety and tolerability in type 3 von Willebrand disease. Blood 2010; 116: Abstract 237.
  • 74
    Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 30317.
  • 75
    De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113: 504957.
  • 76
    De Meyer SF, Vanhoorelbeke K, Chuah MK, Pareyn I, Gillijns V, Hebbel RP, Collen D, Deckmyn H, VandenDriessche T. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 2006; 107: 472836.
  • 77
    Pergolizzi RG, Jin G, Chan D, Pierre L, Bussel J, Ferris B, Leopold PL, Crystal RG. Correction of a murine model of von Willebrand disease by gene transfer. Blood 2006; 108: 8629.
  • 78
    Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost 2012; 10: 242837.